Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer.

The oncologist - 1 Mar 2015

Tack Véronique, Ligtenberg Marjolijn J L, Tembuyser Lien, Normanno Nicola, Vander Borght Sara, Han van Krieken J, Dequeker Elisabeth M C

Abstract excerpt

BACKGROUND: Regulations for the selection of patients with metastatic colorectal cancer for anti-EGFR treatment changed at the end of 2013. The set of mutations to be tested extended from KRAS codons 12 and 13 to KRAS and NRAS exons 2, 3, and 4. A European external quality assessment scheme monit...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Codon
Share to ErbB Receptors
Share to Genotyping Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Patient Selection

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to Quality Assurance, Health Care

Share to ras Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 25657200
DOI: 10.1634/theoncologist.2014-0382
PMCID: PMC4350801

Genes

EGFR
KRAS
NRAS
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25657200-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer.PMID 25657200Read ↗

The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences.Semantic proximity Read ↗

Higher quality of molecular testing, an unfulfilled priority: Results from external quality assessment for KRAS mutation testing in colorectal cancer.Semantic proximity Read ↗

External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds.Semantic proximity Read ↗

Molecular genetics external quality assessment pilot scheme for KRAS analysis in metastatic colorectal cancer.Semantic proximity Read ↗

KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment.Semantic proximity Read ↗

How close are we to standardised extended RAS gene mutation testing? The UK NEQAS evaluation.Semantic proximity Read ↗

The RAS testing in real world management of metastatic colorectal cancer: The results of Italian Laboratories Survey.Semantic proximity Read ↗

RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers.Semantic proximity Read ↗

RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres.Semantic proximity Read ↗

Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing.Semantic proximity Read ↗

KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance.Semantic proximity Read ↗

EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.